UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC., MYLAN LABORATORIES LIMITED, ALEMBIC PHARMACEUTICALS LIMITED, TORRENT PHARMACEUTICALS LIMITED, AND AMERIGEN PHARMACEUTICALS LIMITED
Petitioners,

v.

UCB PHARMA GMBH
Patent Owner.

Patent No. 6,858,650
Case IPR2016-00510

PETITIONER MYLAN PHARMACEUTICALS INC.'S AMENDED LIST OF EXHIBITS PURSUANT TO 37 C.F.R. § 42.63(e)

LIST OF EXHIBITS

Ex. 1001: U.S.P.N. 6,858,650

Ex. 1002: File History for U.S.P.N. 6,858,650

Ex. 1003: Declaration of Dr. Steven Patterson, Ph.D.

Ex. 1004: C.V. for Dr. Steven Patterson, Ph.D

Ex. 1005: "Johansson" – WO 94/11337 Filed 6 November 1992 – "Novel 3,3-Diphenylpropylamines, Their Use and Preparation"

Ex. 1006: "Andersson Review" – BJU International (1999), 84, 923-947 – "The Pharmacological Treatment of Urinary Incontinence"; K-E Andersson, R. Appell, L.D. Cardozo, C. Chapple, H.P. Drutz, A.E. Finkbeiner, F. Haab, and R. Vela Navarrete

Ex. 1007: "Brynne 1997" – International Journal of Clinical Pharmacology and Therapeutics (1997), 35, 287-295 – "Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity"; N. Brynne, M.M.S. Stahl, B. Hallen, P.O. Edlund, L. Palmer, P. Hoglund, and J. Gabrielsson

Ex. 1008: "Thomas" – British Heart Journal (1995), 74, 53-56 – "Concentration dependent cardiotoxicity of terodine in patients treated for urinary incontinence"; S. Thomas, P. Higham, K Hartigan-Go, F. Kamali, P. Wood, R. Campbell, and G. Ford

Ex. 1009: "Detrol® Label" – Pharmacia & Upjohn

Ex. 1010: "Postlind" – Drug Metabolism and Disposition (1998), 26 (4), 289-293 – "Tolterodine, A New Muscarinic Receptor Antagonist, Is Metabolized by Cytochromes P450 2D6 and 3A in Human Liver Microsomes"; H. Postlind, A. Danielson, A.

Lindgren, and S. Andersson

Ex. 1011: "Brynne 1998" – Clinical Pharmacology & Therapeutics (May 1998), 63(5), 529-539 – "Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine"; N. Brynne, P. Dalen, G. Alvan, L. Bertilsson, and J. Gabrielsson

Ex. 1012: "Bundgaard" – Elsevier 1985 – "Design of Prodrugs"

Ex. 1013: "Berge 1977" – Journal of Pharmaceutical Sciences (1977), 66 (1), 1-19 – "Pharmaceutical Salts"; S. Berge, L., Bighley, and D. Monkhouse

Ex. 1014: "Andersson 1998" – Drug Metabolism and Disposition (1998), 26(6), 528-535 – "Biotransformation of tolterodine, a new muscarinic receptor antagonist, in mice, rats, and dogs"; S. Andersson, A. Lindgren, and H. Postlind

Ex. 1015: "Nilvebrant" – Pharmacology and Toxicology (1997), 81, 169-172 – "Antimuscarinic Potency and Bladder Selectivity of PNU-200577, a Major Metabolite of Tolterodine"; L. Nilvebrant, P. Gillberg, and B. Sparf

Ex. 1016: "DeMaagd" – P&T (2012), 37(6), 345-361 – "Management of Urinary Incontinence"; G. DeMaagd and T. Davenport

Ex. 1017: "Appell" – Urology (1997), 50, 90-96 – "Clinical efficacy and safety of tolterodine in the treatment of overactive balder: a pooled analysis"; R. Appell

Ex. 1018: "Ashworth" – Home Care Provider (1997), 2(3), 117-120 – "Is My Antihistamine Safe?"; L. Ashworth

Ex. 1019: "Lipinski" – Advanced Drug Delivery Reviews, 1997

Ex. 1020: "Bundgaard PCT" – WO 92/08459 Filed 11 November 1991 –

"Topical Compositions for Transdermal Delivery of Prodrug Derivatives of Morphine"

Ex. 1021: "AUA Guideline" – American Urological Association Eductatio and Research (2014) – "Diagnosis and Treatment of Overactive Bladder (Non-Neorogenic) in Adults: AUA/SUFU Guideline"; E. Gormley, et al

Ex. 1022: "Pfizer 2012 Press Release" – Aug. 2, 2012 "Study Shows Toviaz is Effective in Reducing Urge Urinary Incontinence in Patients with Overactive Bladder After Suboptimal Response to Detrol LA" – www.pfizer.com

Ex. 1023: "PM360" – April 1, 2012 "Overactive Bladder Market: Managing the Future" – www. pm360online.com

Ex. 1024: "Toviaz® Label" – Pfizer Labs

Ex. 1025: "FDA Approval Letter" –NDA20-771

Ex. 1026: "FDA Guidance" – Applications Covered by Section 505(b)(2) – October 1999 – FDA (CDER)

Ex. 1027: "Gould" – International Journal of Pharmaceutics (1986), 3, 201-217 – "Salt Section for Basic Drugs"; P. Gould

Ex. 1028: "Alabaster" – Discovery & Development of Selective M3 Antagonists for Clinical Use, 60 Life Science 1053 (1997)

Ex. 1029: "Takeuchi" – 1,2,3,4-Tetrahydro-2-Isoquinolinecarboxylate Derivatives: A Novel Class of Selective Muscarinic Antagonists, III, in 213th ACS National Meeting, San Francisco, Abst. 046 (Apr. 13-17, 1997)

Ex. 1030: "Goldberg" – DuP 532, an angiotensin II receptor antagonist: First administration and comparison with losartan, Clinical

	Pharmacology & Therapeutics, January 1997
Ex. 1031:	"Begley" – The Blood-brain Barrier: Principles for TGargeting Peptides and Drugs to the Central Nervous System, J. Phar. Pharmacol. 1996, 48:136-146
Ex. 1032:	Dkt 6 2015-01-28 Summons Returned Executed, Case No. 1:15-cv-00079-GMS, *Pfizer,et al v Mylan Pharmaceutical Inc.*(Dist. of DE)
Ex. 1033:	Declaration of DeForest McDuff, Ph.D.
Ex. 1034:	CV for DeForest McDuff, Ph.D.
Ex. 1035:	Toviaz: Don't Let Overactive Bladder Stop You In Your Tracks
Ex. 1036:	Toviaz U.S. and Worldwide Sales
Ex. 1037:	U.S. OAB Prescriptions and Shares by Drug (2008–2014)
Ex. 1038:	U.S. OAB Sales and Shares by Drug (2008–2014)
Ex. 1039:	U.S. OAB Market Share, Prescriptions, and Sales by Drug (2000–2007)
Ex. 1040:	Prescription Path of Toviaz and Other OABs
Ex. 1041:	Sales Path of Toviaz and Other OABs
Ex. 1042:	Sales Path of Toviaz Compound to Pharmaceutical Industry Benchmarks
Ex. 1043:	Comparison of Toviaz Sales to Compound to Pharmaceutical Industry Benchmarks
Ex. 1044:	Chart of Sales Path of Toviaz
Ex. 1045:	Present Value of Toviaz U.S. Sales
Ex. 1046:	Present Value of Toviaz Worldwide Sales
Ex. 1047:	Estimates of Expected R&D Costs
Ex. 1048:	U.S. OAB Detail Shares by Drug (2008–2015)

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.